Exhibit 10.8
Confidential Materials omitted and filed separately with the
Securities and Exchange Commission. Asterisks denote omissions.
DATE: JANUARY 8, 2007
CRITICAL THERAPEUTICS, INC.
AND
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
AMENDMENT NO. 2 RELATING TO
THE SPONSORED RESEARCH AND LICENSE AGREEMENT
DATED JANUARY 1, 2003
- --------------------------------------------------------------------------------
Page 1
AMENDMENT NO. 2 RELATING TO
SPONSORED RESEARCH AND LICENSE AGREEMENT
BETWEEN
CRITICAL THERAPEUTICS, INC.
AND
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
DATED JANUARY 1, 2003
THIS AMENDMENT NO. 2 is made the 8th day of January 2007.
BETWEEN:
(1) CRITICAL THERAPEUTICS, INC., a Delaware corporation ("CTI"); and
(2) THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH, a New York not-for-profit
corporation ("FEINSTEIN")
RECITALS:
(A) CTI and Feinstein entered into a Sponsored Research and License
Agreement dated January 1, 2003.
(B) The said Sponsored Research and License Agreement was modified by that
certain Letter Agreement between CTI and Feinstein dated February 3,
2004, and was amended by that certain Amendment No. 1 dated June 1,
2006. The Sponsored Research and License Agreement as so modified and
so amended is referred to herein as the "ORIGINAL AGREEMENT".
(C) CTI and Feinstein have agreed to amend the Original Agreement by and
upon the terms of this Amendment No. 2.
OPERATIVE PROVISIONS:
1. INTRODUCTION, DEFINITIONS AND INTERPRETATION
1.1. This Amendment No. 2 is supplemental to the Original Agreement.
1.2. In this Amendment, the expression "THIS AMENDMENT NO. 2" shall mean
this Amendment No. 2, including its recitals and schedules.
1.3. Except where expressly provided to the contrary in this Amendment No.
2:
1.3.1 all capitalized terms used in this Amendment No. 2 shall have
the same meanings as are assigned thereto in the Original
Agreement, as amended by this Amendment No. 2; and
1.3.2 this Amendment No. 2 shall be interpreted in the same manner
as the Original Agreement.
1.4. Reference to clauses and Articles herein are to clauses and Articles in
the Original Agreement.
- --------------------------------------------------------------------------------
Page 2
2. AMENDMENTS
NOW THEREFORE, in consideration of the mutual covenants contained in the
Original Agreement and in this Amendment No. 2 and other good and valuable
consideration the receipt and sufficiency of which is hereby acknowledged, the
parties agree that with effect from the Amendment No. 2 Date (as defined below),
the Original Agreement is hereby amended as follows:
2.1. Article 1 shall be amended by insertion of the following additional
definition after Article 1.2.(b).:
"1.2.(c). AMENDMENT NO. 2 DATE" shall mean January 8, 2007."
2.2. Article 1.13 shall be deleted in its entirety and the following
substituted therefor:
"1.13. "Research Term" shall mean the five-year period starting on
the Effective Date of this Agreement and any extension of this period mutually
agreed upon by CTI and North Shore."
2.3 Article 2.1 shall be deleted in its entirety and the following
substituted therefor:
"2.1 CTI Support. CTI agrees to financially support the Sponsored
Research at Feinstein for the Research Term. The amount of CTI financial support
shall be:
First Research Year Two Hundred Thousand Dollars
($200,000.00)
Second Research Year Two Hundred Thousand Dollars
($200,000.00)
Third Research Year Two Hundred Thousand Dollars
($200,000.00)
Fourth Research Year One Hundred and Fifty Thousand Dollars
($150,000.00)
Fifth Research Year One Hundred and Twenty Thousand Dollars
($120,000.00)
Notwithstanding anything to the contrary in this Agreement, Feinstein shall
invoice CTI for (i) 100% of the financial support for the Fourth Research Year
on or after January 8, 2007, (ii) 25% of the financial support for the Fifth
Research Year on or after April 15, 2007, (iii) 25% of the financial support for
the Fifth Research Year on or after July 15, 2007, (iv) 25% of the financial
support for the Fifth Research Year on or after October 15, 2007, and (v) the
balance of the financial support for the Fifth Research Year on or after January
15, 2008." CTI shall make payment by check or wire transfer to Feinstein for
each invoiced amount within one (1) month of the date of CTI's receipt of any
invoice issued by Feinstein pursuant to the immediately preceding sentence.
2.4 ATTACHMENT A shall be deleted in its entirety and the following
substituted therefor:
- --------------------------------------------------------------------------------
Page 3
"ATTACHMENT A
RESEARCH PLAN: CHOLINERGIC ANTI-INFLAMMATORY PATHWAY (CAP) PROGRAM
1. [**]
2. [**]
3. [**]
4. [**]
5. [**]
6. [**]
2.5. Schedule 1.7 shall be deleted in its entirety and the following
substituted therefor:
"SCHEDULE 1.7
NORTH SHORE PATENT RIGHTS
- ----------------------------------------------------------------------------------------------------------------------
NORTH CTI DOCKET APPLICATION TITLE COUNTRY/ APPLICATION INVENTOR(s) STATUS
SHORE NO. FILE TYPE NO., FILING DATE
REF. NO. AND PRIORITY
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Page 4
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Page 5
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
[**] [**] [**] [**] [**] [**] [**]
- ----------------------------------------------------------------------------------------------------------------------
* Application is assigned to North Shore-Long Island Jewish Research Institute
and University of Pittsburgh of the Commonwealth System for Higher Education
3. NO OTHER AMENDMENT; CONFIRMATION
Save as amended by this Amendment No. 2, the parties hereto confirm that the
Original Agreement shall continue in full force and effect in all respects.
4. COUNTERPARTS
This Amendment No. 2 may be signed in any number of counterparts with the same
effect as if the signatures to each counterpart were upon a single instrument,
and all such counterparts together shall be deemed an original of this Amendment
No. 2.
5. GOVERNING LAW AND JURISDICTION
This Amendment No. 2 shall be governed by and construed in accordance with the
laws of the State of New York without regard to any conflict of laws provisions
thereof.
IN WITNESS whereof the parties have executed and delivered this Amendment No. 2
as of the date first above written.
CRITICAL THERAPEUTICS, INC.
By: /s/ Trevor Phillips, PhD
-----------------------------------------------
Name: Trevor Phillips, PhD
Title: Chief Operating Officer
THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH
By: /s/ Kirk R. Manogue, PhD
-----------------------------------------------
Name: Kirk R. Manogue, PhD
Title: Assistant Vice President, Technology Transfer
- --------------------------------------------------------------------------------
Page 6